New triple-drug combo aims to improve leukemia treatment with fewer side effects
NCT ID NCT06782542
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tests a combination of three drugs (olutasidenib, venetoclax, and azacitidine) in people with a specific genetic subtype of acute myeloid leukemia (IDH1-mutated). The goal is to see if this combo works as well as or better than standard chemotherapy, with fewer side effects. About 16 adults aged 18-75 who are healthy enough for intensive chemo will participate. The study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1 MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.